ASCENT: Sacituzumab govitecan versus physician's-choice chemotherapy in previously treated metastatic triple-negative breast cancer
Treatment: Sacituzumab govitecan 10 mg/kg IV on days 1 and 8 every 21 days versus physician's-choice single-agent chemotherapy.
What did it show? Final analysis: median PFS 4.8 vs 1.7 months (HR 0.41, 95% CI 0.33–0.52); median OS 11.8 vs 6.9 months (HR 0.51, 95% CI 0.42–0.63). These median differences are not NNTs.
Sacituzumab govitecan substantially improved PFS and OS in previously treated metastatic TNBC. Grade ≥3 neutropenia and diarrhoea are clinically important; monitor for febrile neutropenia and manage diarrhoea proactively. The primary efficacy population excluded active brain metastases.
Explore the evidence
Choose a tumour site, then narrow the evidence through discipline, treatment setting and clinical question. Settings use simple shared categories; each clinical question retains the study-specific detail.
Select a tumour site to begin.
How to read the evidence
Every entry should make the clinical consequence easier to see.
01 · What the trial reported
HR, RR, OR or another relative measure, exactly as reported.
02 · What changes for patients
Absolute difference at a defined time point or clinically meaningful unit.
03 · Put it in 100 patients
NNT/NNH when appropriate, always tied to a specified endpoint and time horizon.
About
Dr Rishi P Nair
Clinical Oncology · Evidence-based oncology
The Absolute Effect is a clinician-facing evidence atlas designed to move beyond statistical significance and relative measures toward quantities that are easier to interpret at the bedside.